Evaluation of the Effect of Fluvastatin 40 mg (b.i.d.) in the Prevention of the Development of Vasculopathy of the Graft in de Novo Renal Transplant Patients Transplant

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

84 participants

Study Classification

INTERVENTIONAL

Study Start Date

2001-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Principal objective is to investigate if the treatment with fluvastatin can prevent the progression of vascular graft disease in de novo renal transplant patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Fenofibrate on Kidney Function: a Six-week Randomized Cross-over Trial in Healthy People

NCT00543647

Healthy Volunteers

COMPLETED PHASE1

Effect of Short Term Aliskiren Treatment in Kidney Transplant Patients

NCT01437943

Kidney Disease Kidney Failure, Chronic

TERMINATED PHASE4

Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted

NCT03832114

Glomerulonephritis

COMPLETED PHASE2

The EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study

NCT06059664

Kidney Transplant; Complications

RECRUITING PHASE2

A Research Study Looking Into Levels of the Medicine NNC0385-0434 in the Body and How Well it is Tolerated in Participants With Impaired Kidney Function Compared to Participants With Normal Kidney Function

NCT05094934

Chronic Kidney Disease

TERMINATED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Graft Vasculopathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

fluvastatin 40mg b.i.d.

Group Type ACTIVE_COMPARATOR

Fluvastatin

Intervention Type DRUG

Graft vasculopathy

2

Placebo b.i.d.

Group Type PLACEBO_COMPARATOR

Fluvastatin

Intervention Type DRUG

Graft vasculopathy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fluvastatin

Graft vasculopathy

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients where the investigator expects to prescribe cyclosporine, mycophenolate mofetil and corticosteroids as base immunosuppressive therapy, regardless of their participation in the study.
* Man or woman aged from 17 to 70 years.
* Patients that receive a first or second renal transplant from a non-living donor
* Patients where allograft biopsies may be performed.
* Patients receiving an identical or compatible ABO graft.
* Patients willing to give their written informed consent to all study issues.
* Women with child-bearing potential should use a medically proven contraceptive method during the study.
* Patients able to meet all study requirements.

Exclusion Criteria

* Patients with pre-transplant cholesterol levels above 240 mg/dl (6.2 mmol/l).
* Positive cross-match of T cells or ABO incompatibility with the donor.
* Recipients of multiorgan transplant.
* Patients with diabetes mellitus.
* HIV seropositive or with surface antigen of Hepatitis B .
* Kidney from a donor aged over 65 years.
* Last panel of reactive antibody (PRA) above 50%.
* Women who plan to get pregnant within 12 months, or who are pregnant and/or nursing.
* Patients with a history of cancer in the previous 5 years, except for patients successfully treated with localized carcinoma of squamous or basal cells of the skin, or cervix cancer in situ treated adequately.
* Patients receiving an investigational drug in the 30 days prior to the transplant and/or who will receive an investigational/non-registered drug during the study, except for the use of erythropoietin-stimulating products
* Patients with myocardial infarction within the 6 months prior to the transplant, uncontrollable cardiac arrhythmia or another severe or unstable medical condition probably affecting the safety of the patient or the study objectives.
* Patients with alcohol dependence or drug abuse not solved, or signs of organic lesion caused by alcohol, mental dysfunction or other factors limiting their ability to fully cooperate with the study.
* Patients where it is planned to perform an induction treatment with preparations containing antilymphocyte antibodies (ALG, ATG or OKT-3).
* Patients scheduled to receive cyclosporine i.v. for over 48 hours.
* Patients with liver dysfunction (ALT or AST values or total bilirubin 2 times above the upper limit of the normal ranges of the laboratory values).

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No